Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03061058 |
|
Recruitment Status : Unknown
Verified September 2017 by Yang Yang, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.
Recruitment status was: Recruiting
First Posted : February 23, 2017
Last Update Posted : September 15, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Tumor messenger ribonucleic acid (mRNA) expression levels may have a promising role as potential predictive biomarkers for chemotherapy.
Peritoneal carcinomatosis appears to be the most common pattern of metastasis or recurrence and is associated with poor prognosis in gastric cancer patients. Intraperitoneal chemotherapy is widely accepted strategy in the treatment of peritoneal dissemination.
In this study, our aim is to evaluate the impact of individualized selection of chemotherapeutics and intraperitoneal combined with system chemotherapy on overall survival, disease free survival, response rate, and safety of advanced gastric cancer patients.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Stomach Neoplasms Chemotherapy Effect Chemotherapeutic Toxicity | Drug: Docetaxel Drug: Oxaliplatin Drug: Cisplatin Drug: Irinotecan Drug: Pemetrexed Drug: S1 | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 240 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-label, Randomized, Phase III, Multicenter Clinical Trial Comparing the Efficacy and Safety of Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for Advanced Gastric Cancer |
| Actual Study Start Date : | April 1, 2013 |
| Estimated Primary Completion Date : | December 2018 |
| Estimated Study Completion Date : | December 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Individualized Group
mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels. Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m^2, d1, d15, q4w), intravenous docetaxel (30mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w). Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w). Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m^2, d1, d15, q4w), intravenous docetaxel (90mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w). Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m^2, d1, q3w), and intravenous pemetrexed (350mg/m^2, d1, q3w). |
Drug: Docetaxel
intraperitoneal and/or intravenous Drug: Oxaliplatin intravenous Drug: Cisplatin intraperitoneal Drug: Irinotecan intraperitoneal and/or intravenous Drug: Pemetrexed intraperitoneal and/or intravenous Drug: S1 oral |
|
Active Comparator: Control Group
mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients. Patients in control group will receive intravenous docetaxel (45mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w). |
Drug: Docetaxel
intraperitoneal and/or intravenous Drug: S1 oral |
- Progression-free Survival (PFS) [ Time Frame: up to 1 year ]the follow-up visit of PFS will be performed every 6 weeks
- Overall Survival (OS) [ Time Frame: up to 2 years ]OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost
- Objective Response Rate [ Time Frame: up to 24 weeks ]CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation
- Adverse Events [ Time Frame: up to 1 months ]participants will be followed for the duration of hospital stay
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or metastatic disease, not amenable to curative therapy.
- Patients must have measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1), assessed using imaging techniques (CT or MRI).
- Patients must have enough tumor tissue for mRNA expression test.
- Women of childbearing potential must be non-pregnant (negative pregnancy test within 72 hours prior to chemotherapy, postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential) and nonlactating, and men and women must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for 6 months after therapy completed
- Eastern Cooperative Oncology Group (ECOG) Performance status 0, 1 or 2.
- Absolute neutrophil count (ANC) >=1,500/ul
- Platelets (PLT) >=75,000/ul
- Serum bilirubin <= 1.5 × upper limit of normal (ULN)
- Aspartate transaminase (AST) or alanine aminotransferase (ALT) <= 2.5 × ULN (or <= 5 × ULN in patients with liver metastases)
- Alkaline phosphatase <= 2.5 × ULN (or <= 5 × ULN in patients with liver metastases, or <= 10 × ULN in patients with bone but no liver metastases)
- Albumin >= 25 g/L.
- Creatinine clearance >= 60 mL/min.
- Life expectancy of at least 3 months.
- Signed informed consent.
Exclusion Criteria:
- Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study; the total dose of cisplatin should be less than 300mg/m^2).
- Patients with active (significant or uncontrolled) gastrointestinal bleeding.
- Residual relevant toxicity resulting from previous therapy (with the exception of alopecia), e.g. neurological toxicity ≥ grade 2 NCI-CTCAE 4.0.
- Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.
- History of documented congestive heart failure; angina pectoris requiring medication;evidence of transmural myocardial infarction on ECG; poorly controlled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg); clinically significant valvular heart disease; or high risk uncontrollable arrhythmias.
- Baseline left ventricular ejection fraction (LVEF) < 50% (measured by echocardiography or MUGA).
- Patients with dyspnoea at rest due to complications of advanced malignancy or other disease, or who require supportive oxygen therapy.
- Patients receiving chronic or high dose corticosteroid therapy. (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed).
- Clinically significant hearing abnormality.
- Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- History or clinical evidence of brain metastases.
- Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly controlled diabetes.
- Positive serum pregnancy test in women of childbearing potential.
- Received any investigational drug treatment within 4 weeks of start of study treatment.
- Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if palliative radiotherapy given to bone metastatic site peripherally and patient recovered from any acute toxicity;prior adjuvant radiotherapy is allowed if complete at least 6 months ).
- Major surgery within 4 weeks of start of study treatment, without complete recovery.
- Patients with known active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV).
- Known hypersensitivity to any of the study drugs.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03061058
| Contact: Yang Yang, MD,PhD,MSCR | 0086-18602568379 | wing_young7@hotmail.com | |
| Contact: Baorui Liu, MD, PhD | 0086-13770621908 | baoruiliu07@163.com |
| China, Anhui | |
| Ma'anshan People's Hospital | Recruiting |
| Ma'anshan, Anhui, China | |
| Contact: Fenglin Zhang, MD | |
| Contact: Fangbo Cui, MD | |
| China, Jiangsu | |
| Jiangyin People's Hospital | Recruiting |
| Jiangyin, Jiangsu, China | |
| Contact: Weisheng Shen, MD | |
| Contact: Lei Xi, MD | |
| Nanjing Gaochun People's Hospital | Recruiting |
| Nanjing, Jiangsu, China, 210000 | |
| Contact: Rongfu Wei, MD | |
| Contact: Yajun Xin, MD | |
| Nanjing Lishui People's Hospital | Recruiting |
| Nanjing, Jiangsu, China, 210000 | |
| Contact: Chunlan Nie, MD | |
| Contact: Hui Xu, MD | |
| The Comprehensive Cancer Center of Nanjing Drum Tower Hospital | Recruiting |
| Nanjing, Jiangsu, China, 210008 | |
| Contact: Yang Yang, MD,PhD,MSCR 0086-18602568379 wing_young7@hotmail.com | |
| Contact: Baorui Liu, MD, PhD 0086-13770621908 baoruiliu07@163.com | |
| Suqian People's Hospital | Recruiting |
| Suqian, Jiangsu, China | |
| Contact: Chuanwen You, MD | |
| Contact: Qing Zhu, MD | |
| Xuzhou Central Hospital | Recruiting |
| Xuzhou, Jiangsu, China | |
| Contact: Sanyuan Sun, MD | |
| Contact: Yuan Yuan, MD | |
| Affiliated Hospital of Jiangsu University | Recruiting |
| Zhenjiang, Jiangsu, China | |
| Contact: Xiaoqing Li, MD | |
| Contact: Meilian Cheng, MD | |
| Responsible Party: | Yang Yang, Principal investigator, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| ClinicalTrials.gov Identifier: | NCT03061058 |
| Other Study ID Numbers: |
AGC-PC |
| First Posted: | February 23, 2017 Key Record Dates |
| Last Update Posted: | September 15, 2017 |
| Last Verified: | September 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Docetaxel Oxaliplatin Irinotecan |
Pemetrexed Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |